Loading
Recurrent Malignant Mesothelioma / Cediranib Maleate / Laboratory Biomarker Analysis · Phase 1/2 Trial
ClinicalTrials.gov · September 9, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a clinical trial registration for a planned phase 1/2 study combining cediranib with cisplatin and pemetrexed in malignant pleural mesothelioma. No results have been posted in the registry, so no efficacy, safety, or tolerability data are available to evaluate. The record documents the study design, primary endpoints (MTD in phase 1; PFS in phase 2), and planned enrollment, but is not evidence of clinical benefit.
Phase 1/2, Interventional, Randomized, Parallel, Double masking, Treatment purpose. Epithelioid Mesothelioma, Pleural Malignant Mesothelioma, Recurrent Malignant Mesothelioma, Sarcomatoid Mesothelioma; age from 18 Years. Intervention: Arm I (pemetrexed disodium, cisplatin, cediranib maleate)). Compared with: Arm II (pemetrexed disodium, cisplatin, placebo) — Active Comparator. n = 117. 230 sites: United States.
This is a clinical trial registration for a planned phase 1/2 study combining cediranib with cisplatin and pemetrexed in malignant pleural mesothelioma. No results have been posted in the registry, so no efficacy, safety, or tolerability data are available to evaluate. The record documents the study design, primary endpoints (MTD in phase 1; PFS in phase 2), and planned enrollment, but is not evidence of clinical benefit.
This is a registry record with no results posted; no efficacy, safety, or adverse event data are available.
This registry record describes a planned trial but does not provide results. Clinicians and researchers should not draw any conclusion about the efficacy, safety, or tolerability of cediranib combined with cisplatin and pemetrexed until results are published or posted.
This is a Phase 1/2 trial registration with no results posted; it describes planned enrollment and endpoints only, without efficacy or safety outcomes, making it an early-stage design document rather than evidence of clinical benefit.
As stated by the source record.
Quoted from the source exactly as published.
This registry record describes a planned trial but does not provide results. Clinicians and researchers should not draw any conclusion about the efficacy, safety, or tolerability of cediranib combined with cisplatin and pemetrexed until results are published or posted.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT01064648). This is a study registration, not published results. Lead sponsor: National Cancer Institute (NCI). Recruitment status: ACTIVE_NOT_RECRUITING. Phase: PHASE1, PHASE2. Study type: INTERVENTIONAL. Enrollment: 117 participants (ACTUAL). Conditions: Epithelioid Mesothelioma, Pleural Malignant Mesothelioma, Recurrent Malignant Mesothelioma, Sarcomatoid Mesothelioma. Interventions: DRUG: Cediranib Maleate; DRUG: Cisplatin; OTHER: Laboratory Biomarker Analysis; DRUG: Pemetrexed Disodium; OTHER: Placebo Administration. Primary outcome measures: Maximum Tolerated Dose of Cediranib in Combination With Cisplatin and Pemetrexed (Phase I) , Weekly during first cycle (1cycle = 21 days). Then will be reported every cycle while patient is on treatment.; Progression-free Survival (Phase II) , From date of registration to date of first documentation of progression or symptomatic deterioration, or death due to any cause, whichever came first, assessed up to 5 years.Disease assessment will be repeated every 6 weeks until disease progression.. Brief summary: This randomized phase I/II trial is studying the side effects and best dose of cediranib maleate when given together with pemetrexed disodium and cisplatin and to see how well it works in treating patients with malignant pleural mesothelioma. Drugs used in chemotherapy, pemetrexed disodium and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Cediranib maleate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving pemetrexed disodium and cisplatin together with cediranib maleate may kill more tumor cells.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.